Huang Vanthida, Brown William J, Rybak Michael J
Anti-Infective Research Laboratory, Department of Pharmacy Practice-4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 48201, USA.
Antimicrob Agents Chemother. 2004 Jul;48(7):2719-23. doi: 10.1128/AAC.48.7.2719-2723.2004.
We examined the activity of CB-181963, a novel cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA) (n = 200), methicillin-susceptible S. aureus (MSSA) (n = 50), glycopeptide-intermediate Staphylococcus species (GISS) (n = 47), and VRSA (n = 2) isolates. CB-181963 exhibited MIC profiles similar to those of linezolid against MRSA and GISS; however, activity against MSSA was similar to that of vancomycin. Time-kill study results of investigations of activity against MRSA, MSSA, and GISS at 24 h were as follows: CB-181963 activity = vancomycin activity > linezolid activity (P < 0.001); CB-181963 = quinupristin-dalfopristin = vancomycin > linezolid (P < 0.05); CB-181963 > linezolid (P = 0.003); and CB-181963 = quinupristin-dalfopristin = vancomycin. CB-181963 may provide an alternative treatment for multidrug-resistant staphylococci.
我们检测了新型头孢菌素CB - 181963对耐甲氧西林金黄色葡萄球菌（MRSA，n = 200株）、甲氧西林敏感金黄色葡萄球菌（MSSA，n = 50株）、糖肽类中介葡萄球菌属（GISS，n = 47株）及耐万古霉素金黄色葡萄球菌（VRSA，n = 2株）分离株的活性。CB - 181963对MRSA和GISS的最低抑菌浓度（MIC）谱与利奈唑胺相似；然而，其对MSSA的活性与万古霉素相似。针对MRSA、MSSA和GISS在24小时的活性进行的时间杀菌研究结果如下：CB - 181963活性 = 万古霉素活性 > 利奈唑胺活性（P < 0.001）；CB - 181963 = 奎奴普丁 - 达福普汀 = 万古霉素 > 利奈唑胺（P < 0.05）；CB - 181963 > 利奈唑胺（P = 0.003）；且CB - 181963 = 奎奴普丁 - 达福普汀 = 万古霉素。CB - 181963可能为多重耐药葡萄球菌提供一种替代治疗方法。
